Atyr Pharma Inc (NASDAQ: ATYR) on Tuesday, plunged -9.78% from the previous trading day, before settling in for the closing price of $3.58. Within the past 52 weeks, ATYR’s price has moved between $1.42 and $4.66.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 429.49% over the last five years. The company achieved an average annual earnings per share of 17.86%. With a float of $86.00 million, this company’s outstanding shares have now reached $88.86 million.
The firm has a total of 59 workers. Let’s measure their productivity. In terms of profitability, gross margin is -390.64%, operating margin of -28899.57%, and the pretax margin is -27243.4%.
Atyr Pharma Inc (ATYR) Insider Activity
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Atyr Pharma Inc is 3.22%, while institutional ownership is 62.66%. The most recent insider transaction that took place on Mar 17 ’25, was worth 15,000. In this transaction Director of this company bought 3,750 shares at a rate of $4.00, taking the stock ownership to the 9,750 shares. Before that another transaction happened on Feb 04 ’25, when Company’s Chief Financial Officer sold 1,254 for $3.78, making the entire transaction worth $4,740. This insider now owns 31,763 shares in total.
Atyr Pharma Inc (ATYR) Earnings and Forecasts
According to the Wall Street analysts, stocks earnings will be around 17.86% per share during the next fiscal year.
Atyr Pharma Inc (NASDAQ: ATYR) Trading Performance Indicators
Atyr Pharma Inc (ATYR) is currently performing well based on its current performance indicators. A quick ratio of 5.48 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 1247.87.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.87, a number that is poised to hit -0.19 in the next quarter and is forecasted to reach -0.60 in one year’s time.
Technical Analysis of Atyr Pharma Inc (ATYR)
Analysing the last 5-days average volume posted by the [Atyr Pharma Inc, ATYR], we can find that recorded value of 1.02 million was lower than the volume posted last year of 1.3 million. As of the previous 9 days, the stock’s Stochastic %D was 58.33%. Additionally, its Average True Range was 0.27.
During the past 100 days, Atyr Pharma Inc’s (ATYR) raw stochastic average was set at 39.41%, which indicates a significant decrease from 46.34% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 71.22% in the past 14 days, which was lower than the 85.65% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $3.33, while its 200-day Moving Average is $2.93. Now, the first resistance to watch is $3.46. This is followed by the second major resistance level at $3.69. The third major resistance level sits at $3.81. If the price goes on to break the first support level at $3.11, it is likely to go to the next support level at $2.99. Should the price break the second support level, the third support level stands at $2.76.
Atyr Pharma Inc (NASDAQ: ATYR) Key Stats
Market capitalization of the company is 287.01 million based on 88,859K outstanding shares. Right now, sales total 240 K and income totals -64,020 K. The company made 0 K in profit during its latest quarter, and -14,970 K in sales during its previous quarter.
